Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

United States

University of Alabama at Birmingham, Birmingham, Alabama

University of California, San Francisco, San Francisco, California

University of Texas Health Science Center at Houston (UTHealth Houston), Houston, Texas